On 2026-08-21, a trial update was recorded for the study registered as NCT06531824. The trial is titled "EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)." This is a Phase 3 study, and its current status is listed as recruiting.
The trial is evaluating BI 690517 in combination with empagliflozin, according to the registered title. No results have been reported for this study as of this update. The status reflects only that recruitment is ongoing, not any outcome or finding.
This update relates to angiotensin II, which carries an approved regulatory status. The event data provided does not include information on trial results, patient numbers, or safety findings. Readers should note that a recruiting status indicates the study is still enrolling participants and has not concluded.
Further details, including the full protocol and eligibility criteria, are available through the official trial registry listing at the provided identifier. For more background on this compound generally, readers can consult the compound overview.